Louisiana vs New Jersey on USAspending: $4.7B vs $8.1B

Sixteen New Jersey awards for each Louisiana award

These figures are USAspending.gov obligations, not Treasury outlays. New Jersey’s $8.1B stock sits $3.4 billion above Louisiana’s $4.7B. Place of performance in the award file is the scoring rule. New Jersey has more people (9,500,851 versus 4,597,740) and a vastly busier file. Louisiana still posts the higher per-capita reading and the larger FY2026 window.

New Jersey’s $8,084,032,234 is spread across 1,162,765 records. Louisiana’s $4,707,913,049 sits on 72,577. That is about 16 New Jersey awards for each Louisiana award. Dollars favor New Jersey; paperwork volume favors New Jersey as well. Intensity and recency do not.

New Jersey’s 1,162,765 awards on $8,084,032,234 versus Louisiana’s 72,577 awards on $4,707,913,049 is a 16-to-1 paperwork gulf. FY2026 of $878,702,039 versus $1,232,995,601 already favors Louisiana. People of 9,500,851 versus 4,597,740 produce $92.49 versus $268.17. Ships versus pharmaceuticals is mix. A million-row file can still trail on the latest year and on intensity.

Louisiana’s $268.17 versus New Jersey’s $92.49

Louisiana’s 4,597,740 residents against $4.7B produce $268.17 per capita. New Jersey’s 9,500,851 residents against $8.1B produce $92.49. Intensity in Louisiana is nearly three times New Jersey’s even though New Jersey holds the larger stacked total and the million-row file.

A $268.17 per-person reading is an intensity fact attached to $4.7B, not a household check. New Jersey’s $92.49 is attached to $8.1B. This table scores USAspending place of performance, not GDP. A 72,577-award file on $4.7B is consistent with a heavier typical booking than a 1,162,765-award file on $8.1B.

Ships in Louisiana, pharmaceuticals in New Jersey

Louisiana’s top industry is ship building and repairing. New Jersey’s is pharmaceutical preparation manufacturing. Those NAICS labels mark the largest grouping in each state’s file. Shipyard awards and drug-manufacturing awards are different lead products sitting on $4.7B and $8.1B stocks.

A ship-building lead inside Louisiana’s 72,577-award file can concentrate yard work without explaining every dollar. A pharmaceutical-preparation lead inside New Jersey’s 1,162,765-award file can sit among many smaller actions. Mix and scale both differ. Neither label is the entire stock.

FY2026: $1.23B in Louisiana vs $878.7M in New Jersey

FY2026 obligations are $1,232,995,601 in Louisiana and $878,702,039 in New Jersey. Louisiana leads the latest year, reversing a stacked ranking that favors New Jersey. Recency questions belong in FY2026. The $4.7B and $8.1B totals remain the full USAspending.gov aggregate this comparison uses. Both years are obligations, not outlays.

Do not divide those FY figures by Louisiana’s 72,577 or New Jersey’s 1,162,765 all-years awards. Per capita of $268.17 on 4,597,740 residents versus $92.49 on 9,500,851 residents is the intensity comparison. FY2026 is the cut that reverses the dollar ranking. Stacked totals still favor New Jersey.

Louisiana’s $1,232,995,601 FY2026 versus New Jersey’s $878,702,039 already reverses $4,707,913,049 versus $8,084,032,234. 72,577 awards versus 1,162,765 awards and 4,597,740 residents versus 9,500,851 residents produce $268.17 versus $92.49. A million-row file can still trail on the latest year. Ships versus pharmaceuticals is mix. Both years are obligations.

A row gulf with inverted recency

New Jersey leads stacked dollars ($8.1B vs $4.7B), award count (1,162,765 vs 72,577), and population (9,500,851 vs 4,597,740). Louisiana leads per capita ($268.17 vs $92.49) and FY2026 ($1.23B vs $878.7M). The distinctive facts are the 16-to-1 row gap and the recency inversion.

Ship building and repairing versus pharmaceutical preparation manufacturing is mix inside files that contain many other industries. Use the Louisiana and New Jersey hubs for agencies and recipients. Keep both stocks labeled as USAspending.gov obligations.

A 16-to-1 row gap that FY2026 already reverses

New Jersey’s 1,162,765 awards on $8,084,032,234 versus Louisiana’s 72,577 awards on $4,707,913,049 is the paperwork gulf. FY2026 of $878,702,039 versus $1,232,995,601 is the recency ranking, and it already favors Louisiana. Per capita of $92.49 on 9,500,851 residents versus $268.17 on 4,597,740 residents is the intensity ranking.

Ship building and repairing versus pharmaceutical preparation manufacturing is mix. A million-row file and a 72,577-row file can sit on stocks that still invert on the latest year. Both figures are USAspending.gov obligations by place of performance, not outlays. Open the state hubs for agencies and recipients.

Questions

Which state has more federal spending, Louisiana or New Jersey?

New Jersey leads in stacked USAspending.gov obligations: $8,084,032,234 versus Louisiana’s $4,707,913,049. New Jersey has far more awards (1,162,765 vs 72,577) and more people (9,500,851 vs 4,597,740). Spending per capita is $268.17 in Louisiana and $92.49 in New Jersey. FY2026 obligations are $1.23B and $878.7M. These are obligations, not Treasury outlays.

Does Louisiana outpace New Jersey in FY2026?

Yes. FY2026 obligations are $1,232,995,601 in Louisiana versus $878,702,039 in New Jersey. The stacked ranking still favors New Jersey ($8.1B vs $4.7B). Per capita is $268.17 versus $92.49. Award counts are 72,577 and 1,162,765. Populations are 4,597,740 and 9,500,851.

What industries lead Louisiana and New Jersey federal awards?

Louisiana’s top industry is ship building and repairing. New Jersey’s is pharmaceutical preparation manufacturing. Those slices sit on $4.7B and $8.1B obligation stocks. They mark the largest grouping in each file, not every award in either state. Award counts are 72,577 in Louisiana and 1,162,765 in New Jersey.

Are Louisiana vs New Jersey figures Treasury outlays?

No. SpendingVault uses USAspending.gov obligations. Outlays are cash payments and can lag. The $4.7B and $8.1B stacked totals and FY2026 amounts of $1.23B and $878.7M measure award commitments by place of performance, not Monthly Treasury Statement payments.